ArticleCurrent rheumatology reports2008
Dehydroepiandrosterone in systemic lupus erythematosus.
Article in Current rheumatology reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Dehydroepiandrosterone for women in the peri- or postmenopausal phase.The Cochrane database of systematic reviews · 2015Pooled it
- Integrated metabolomic profiling identifies citrate as novel diagnostic biomarker for Anti-MDA5-Positive dermatomyositis.Arthritis research & therapy · 2025Article
- Rebalancing immunity: The emerging role of selective estrogen receptor modulators in immunity and autoimmunity.Current trends in immunology · 2025Article
- Autoimmune Responses and Therapeutic Interventions for Systemic Lupus Erythematosus: A Comprehensive Review.Endocrine, metabolic & immune disorders drug targets · 2024Review
- Cumulative physiological stress is associated with age-related changes to peripheral T lymphocyte subsets in healthy humans.Immunity & ageing : I & A · 2023Article
- Fighting Fatigue in Systemic Lupus Erythematosus: Experience of Dehydroepiandrosterone on Clinical Parameters and Patient-Reported Outcomes.Journal of clinical medicine · 2022Article
- Dehydroepiandrostenedione sulphate (DHEAS) levels predict high risk of rheumatoid arthritis (RA) in subclinical hypothyroidism.PloS one · 2021Article
- Through the Looking-Glass: Reevaluating DHEA Metabolism Through HSD3B1 Genetics.Trends in endocrinology and metabolism: TEM · 2020Review
- Review
- Fatigue, Sleep, and Autoimmune and Related Disorders.Frontiers in immunology · 2019Review
- Reversing the immune ageing clock: lifestyle modifications and pharmacological interventions.Biogerontology · 2018Review
- Hypothalamic-Pituitary-Adrenal Hypofunction in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) as a Consequence of Activated Immune-Inflammatory and Oxidative and Nitrosative Pathways.Molecular neurobiology · 2017Review
- Review
- Genetics of androgen metabolism in women with infertility and hypoandrogenism.Nature reviews. Endocrinology · 2015Review
- Prolactin and Dehydroepiandrosterone Levels in Women with Systemic Lupus Erythematosus: The Role of the Extrapituitary Prolactin Promoter Polymorphism at -1149G/T.Journal of immunology research · 2015Article
- Estrogen receptor alpha deficiency protects against development of cognitive impairment in murine lupus.Journal of neuroinflammation · 2014Article
- Understanding how we age: insights into inflammaging.Longevity & healthspan · 2013Article
- Ethnic differences in DNA methyltransferases expression in patients with systemic lupus erythematosus.Journal of clinical immunology · 2013Article
- Sex-specific differences in the relationship between genetic susceptibility, T cell DNA demethylation and lupus flare severity.Journal of autoimmunity · 2012Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Dehydroepiandrosterone (DHEA) is a weak androgen that exerts pleomorphic effects on the immune system. The hormone has no known receptor, and consequently, its mechanism of action on immunocompetent cells remains poorly understood. Interestingly, serum levels of DHEA are decreased in patients with inflammatory diseases including lupus, and these levels seem to correlate inversely with disease activity. Following encouraging studies demonstrating beneficial effects of DHEA supplementation in murine lupus models, several clinical studies have tested the effect of DHEA in lupus patients. DHEA treatment could improve overall quality-of-life assessment measures and glucocorticoid requirements in some lupus patients with mild to moderate disease; however, DHEA's effect on disease activity in lupus patients remains controversial. Long-term safety studies are required in light of the reported effect of DHEA supplementation in lowering high-density lipoprotein cholesterol in lupus patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.